U.S. Castrate-resistant Prostate Cancer Market Size & Outlook
U.S. castrate-resistant prostate cancer market, 2016-2027 (US$M)
Related Markets
U.S. castrate-resistant prostate cancer market highlights
- The U.S. castrate-resistant prostate cancer market generated a revenue of USD 4,086.3 million in 2018 and is expected to reach USD 6,798.2 million by 2027.
- The U.S. market is expected to grow at a CAGR of 5.8% from 2019 to 2027.
- In terms of segment, hormonal therapy was the largest revenue generating therapy in 2018.
- Immunotherapy is the most lucrative therapy segment registering the fastest growth during the forecast period.
Castrate-resistant prostate cancer market data book summary
| Market revenue in 2018 | USD 4,086.3 million |
| Market revenue in 2027 | USD 6,798.2 million |
| Growth rate | 5.8% (CAGR from 2018 to 2027) |
| Largest segment | Hormonal therapy |
| Fastest growing segment | Immunotherapy |
| Historical data | 2016 - 2017 |
| Base year | 2018 |
| Forecast period | 2019 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy |
| Key market players worldwide | Sanofi SA, Johnson & Johnson, Pfizer Inc, Astellas Pharma Inc, Bayer AG |
Other key industry trends
- In terms of revenue, U.S. accounted for 50.2% of the global castrate-resistant prostate cancer market in 2018.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
- In North America, U.S. castrate-resistant prostate cancer market is projected to lead the regional market in terms of revenue in 2027.
- Canada is the fastest growing regional market in North America and is projected to reach USD 590.0 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Castrate-resistant Prostate Cancer Market Scope
Castrate-resistant Prostate Cancer Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. castrate-resistant prostate cancer market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to castrate-resistant prostate cancer market will help companies and investors design strategic landscapes.
Hormonal therapy was the largest segment with a revenue share of 82.8% in 2018. Horizon Databook has segmented the U.S. castrate-resistant prostate cancer market based on chemotherapy, hormonal therapy, immunotherapy, radiotherapy covering the revenue growth of each sub-segment from 2016 to 2027.
Reasons to subscribe to U.S. castrate-resistant prostate cancer market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. castrate-resistant prostate cancer market databook
-
Our clientele includes a mix of castrate-resistant prostate cancer market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. castrate-resistant prostate cancer market, including forecasts for subscribers. This country databook contains high-level insights into U.S. castrate-resistant prostate cancer market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. castrate resistant prostate cancer market size, by therapy, 2016-2027 (US$M)
U.S. Castrate-resistant Prostate Cancer Market Share, 2018 & 2027 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
